Regulatory Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Therapeutic
Prescription Only
Formulation Information
OINTMENT
**Dosage and Administration** **Populations** _Adults and Children: BACTROBAN_ nasal ointment should be applied to the anterior nostrils 2 to 3 times a day, as follows: A small amount of ointment, about the size of a match head is squeezed on the little finger or a cotton-tipped applicator, if available. The ointment is applied to the inside of one nostril. This is repeated for the other nostril. The nostrils are closed by pressing the sides of the nose together. This spreads the ointment throughout the nostrils. Nasal carriage should normally clear within 3 to 5 days of commencing treatment. Dosage should not exceed 10 days. Do not mix with other preparations as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the mupirocin in the ointment.
NASAL
Medical Information
**Indications** Elimination of nasal carriage of staphylococci, including methicillin-resistant _Staphylococcus aureus_ (MRSA). For the treatment of bacterial skin infections _BACTROBAN_ ointment should be used. See package leaflet for this _BACTROBAN_ formulation or contact the manufacturer for details. – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
**Contraindications** _BACTROBAN_ nasal ointment should not be given to patients with a history of hypersensitivity to mupirocin or any of the constituents of the preparations.
R01AX06
mupirocin
Manufacturer Information
GLAXOSMITHKLINE PTE LTD
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations)
Active Ingredients
Documents
Package Inserts
Bactroban Nasal Ointment PI.pdf
Approved: March 28, 2018